Long-Term Treatment of Postmenopausal Osteoporosis.
Brown JP.
Endocrinol Metab (Seoul). 2021 Jun;36(3):544-552. doi: 10.3803/EnM.2021.301. Epub 2021 Jun 22.
Puerarin improves OVX-induced osteoporosis by regulating phospholipid metabolism and biosynthesis of unsaturated fatty acids based on serum metabolomics.
Li B, Wang Y, Gong S, Yao W, Gao H, Liu M, Wei M.
Phytomedicine. 2022 Jul 20;102:154198. doi: 10.1016/j.phymed.2022.154198. Epub 2022 May 21.
Denosumab Discontinuation.
Sølling AS, Tsourdi E, Harsløf T, Langdahl BL.
Curr Osteoporos Rep. 2023 Feb;21(1):95-103. doi: 10.1007/s11914-022-00771-6. Epub 2022 Dec 24.
Estrogen and bone metabolism.
Väänänen HK, Härkönen PL.
Maturitas. 1996 May;23 Suppl:S65-9. doi: 10.1016/0378-5122(96)01015-8.
Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk.
Lim SY.
Womens Health (Lond). 2022 Jan-Dec;18:17455057221125577. doi: 10.1177/17455057221125577.
Glucocorticoid-induced osteoporosis: an update.
Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A.
Trends Endocrinol Metab. 2006 May-Jun;17(4):144-9. doi: 10.1016/j.tem.2006.03.009.
Teriparatide for glucocorticoid-induced osteoporosis.
Diez-Perez A, Sole E.
J Rheumatol. 2012 Mar;39(3):461-2. doi: 10.3899/jrheum.111629.
Estrogen deficiency induces bone loss through the gut microbiota.
Guan Z, Xuanqi Z, Zhu J, Yuan W, Jia J, Zhang C, Sun T, Leng H, Jiang C, Xu Y, Song C.
Pharmacol Res. 2023 Oct;196:106930. doi: 10.1016/j.phrs.2023.106930. Epub 2023 Sep 16.
Teriparitide update.
Silverman SL, Nasser K.
Rheum Dis Clin North Am. 2011 Aug;37(3):471-7, vii. doi: 10.1016/j.rdc.2011.08.002.
Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.
Shane E, Shiau S, Recker RR, Lappe JM, Agarwal S, Kamanda-Kosseh M, Bucovsky M, Stubby J, Cohen A.
J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1528-e1540. doi: 10.1210/clinem/dgab850.
